Vaxart to Showcase Oral Vaccine Platform and Strategic Vision at BIO 2026 and Taiwan Biotech Forum
Rhea-AI Summary
Vaxart (OTCQX: VXRT) will showcase its oral vaccine platform and strategic vision at the 2026 Taiwan Biotech Forum and BIO International Convention in San Diego.
Company leaders will discuss targeting mucosal immunity with oral tablets, which may reduce reliance on injections and cold-chain logistics.
Positive
- None.
Negative
- None.
News Market Reaction – VXRT
In the Jun 15 session, VXRT gained 2.68%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 09 | Conference participation | Neutral | -1.5% | Announcement of participation in BTIG Infectious Disease Day 2026. |
| Jun 08 | Proxy campaign letter | Neutral | -5.4% | Company urges shareholders to back board slate amid proxy contest. |
| Jun 01 | Definitive proxy filed | Neutral | -2.3% | Definitive proxy and shareholder letter on governance and pipeline. |
| May 19 | Prelim proxy & letter | Neutral | -1.6% | Preliminary proxy and open letter ahead of contested annual meeting. |
| May 07 | Earnings & update | Positive | -5.4% | Q1 2026 results with revenue, net income, and cash runway to Q2 2027. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent VXRT headlines, including proxy materials and conference participation, often coincided with modest share price declines, with only the Q1 2026 earnings update showing a clear divergence where positive fundamentals met a negative price reaction.
Over the past months, VXRT has focused on governance matters and advancing its oral vaccine platform. Proxy-related communications on May 19, 2026, June 1, 2026, and June 8, 2026 outlined a contested election and cash runway into Q2 2027, while the May 7, 2026 update reported $61.0M cash, $39.2M revenue, and $5.2M net income for Q1 2026. Today’s BIO/Taiwan forum participation fits the pattern of visibility and investor-relations activity around the oral vaccine platform rather than a discrete clinical or financial catalyst.
Key Terms
oral recombinant vaccines medical
precision medicine medical
mucosal immunity medical
cold-chain logistics technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform, today announced that members of its management team will participate in two upcoming events surrounding the BIO International Convention, taking place June 22-25, 2026, at the San Diego Convention Center in San Diego, CA.
2026 Taiwan Biotech Forum
Date: Sunday, June 21, 2026
Location: The Westin San Diego Gaslamp Quarter
Time: 1:30pm – 5:30pm PT
Sean Tucker, Ph.D., Chief Scientific Officer, will participate in a panel discussing innovative therapeutic modalities in precision medicine.
2026 BIO International Convention
Date: Tuesday, June 23, 2026
Location: San Diego Convention Center, Storytelling Stage (Booth #3035)
Time: 3:15pm – 3:35pm PT
Steve Lo, Chief Executive Officer, and Dr. Tucker will present on the innovation, development and consumer friendly approach of the company’s oral vaccine tablet platform. The discussion will highlight how targeting mucosal immunity via an oral pill could eliminate reliance on traditional needle injections and cold-chain logistics, offering a modern solution to improve global health equity and pandemic readiness.
About Vaxart
Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the Company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus, and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.
Contact
Vaxart Media and Investor Relations:
FINN Partners
IR@vaxart.com
